Renal Clear Cell Carcinoma Clinical Trial
Official title:
A Tissue Collection Study in Patients With Renal Clear Cell Carcinoma Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells
T Cell Receptor-engineered T-cell therapy (TCR T-cell therapy) offers a potentially transformative approach to treating cancer, but is currently limited by the lack of known targets (Maus and June, 2016; Ping et al., 2018). Arguably the most clinically meaningful way to discover new targets and TCRs for TCR T-cell therapy is to study the tumorinfiltrating lymphocytes of patients that are actively responding to immune checkpoint inhibitor (ICI) therapy. These T cells are clonally expanded as a result of checkpoint inhibition and are responsible for the patient's clinical response. The goal of this study is to acquire tumor and blood samples from up to 40 patients with renal cell carcinoma (RCC) malignancies who respond to ICI therapy. T cells will be isolated from these samples and the targets of their TCRs determined using TScan's genome-wide, high-throughput target ID technology. The expected outcome of this study is the discovery of a collection of new targets for TCR T-cell therapy, along with associated TCRs that will then be developed as novel therapies for patients with similar malignancies.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02819596 -
MEDI4736 Combinations in Metastatic Renal Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06211790 -
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
|
Phase 2 |